Compare IPCA Labs with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUPRIYA LIFESCIENCE - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUPRIYA LIFESCIENCE IPCA LABS/
SUPRIYA LIFESCIENCE
 
P/E (TTM) x 25.4 - - View Chart
P/BV x 4.9 10.5 46.8% View Chart
Dividend Yield % 0.4 0.2 284.8%  

Financials

 IPCA LABS   SUPRIYA LIFESCIENCE
EQUITY SHARE DATA
    IPCA LABS
Mar-21
SUPRIYA LIFESCIENCE
Mar-21
IPCA LABS/
SUPRIYA LIFESCIENCE
5-Yr Chart
Click to enlarge
High Rs2,456NA-   
Low Rs1,371NA-   
Sales per share (Unadj.) Rs423.347.2 896.4%  
Earnings per share (Unadj.) Rs90.616.9 535.2%  
Cash flow per share (Unadj.) Rs107.117.8 600.3%  
Dividends per share (Unadj.) Rs4.000.54 740.7%  
Avg Dividend yield %0.20- 
Book value per share (Unadj.) Rs370.636.8 1,008.5%  
Shares outstanding (eoy) m126.8573.18 173.3%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x4.50-   
Avg P/E ratio x21.10-  
P/CF ratio (eoy) x17.90-  
Price / Book Value ratio x5.20-  
Dividend payout %4.43.2 138.2%   
Avg Mkt Cap Rs m242,7280-   
No. of employees `000NANA-   
Total wages/salary Rs m10,136328 3,093.9%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m53,6993,456 1,553.7%  
Other income Rs m1,292109 1,190.0%   
Total revenues Rs m54,9913,565 1,542.7%   
Gross profit Rs m14,8121,673 885.4%  
Depreciation Rs m2,09267 3,132.2%   
Interest Rs m12341 300.7%   
Profit before tax Rs m13,8901,674 829.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,401436 551.2%   
Profit after tax Rs m11,4881,238 927.8%  
Gross profit margin %27.648.4 57.0%  
Effective tax rate %17.326.0 66.4%   
Net profit margin %21.435.8 59.7%  
BALANCE SHEET DATA
Current assets Rs m34,3702,664 1,290.2%   
Current liabilities Rs m11,3311,460 776.0%   
Net working cap to sales %42.934.8 123.2%  
Current ratio x3.01.8 166.3%  
Inventory Days Days491 9,462.9%  
Debtors Days Days678 7.1%  
Net fixed assets Rs m26,2951,794 1,465.5%   
Share capital Rs m254146 173.3%   
"Free" reserves Rs m46,7632,543 1,838.8%   
Net worth Rs m47,0172,689 1,748.2%   
Long term debt Rs m3650-   
Total assets Rs m60,6644,458 1,360.7%  
Interest coverage x114.242.0 271.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.8 114.2%   
Return on assets %19.128.7 66.7%  
Return on equity %24.446.0 53.1%  
Return on capital %29.663.8 46.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m27,1720-   
Fx outflow Rs m7,9490-   
Net fx Rs m19,2230-   
CASH FLOW
From Operations Rs m10,901799 1,363.9%  
From Investments Rs m-5,207-474 1,098.3%  
From Financial Activity Rs m-3,058-149 2,048.1%  
Net Cashflow Rs m2,636176 1,498.9%  

Share Holding

Indian Promoters % 46.3 68.2 67.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 44.0 14.9 295.8%  
FIIs % 11.0 7.1 154.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.7 31.8 169.1%  
Shareholders   115,335 82,578 139.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)

After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

How to Find the Next Multibagger Stock in the Market(Profit Hunter)

Jun 17, 2022

The #1 make or break factor in your portfolio you shouldn't ignore.

Is the Market Correction Over?(Fast Profits Daily)

Jun 17, 2022

In this video I'll show you why I think the market correction could be coming to an end.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jul 1, 2022 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - MEDPLUS HEALTH SERVICES COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS